NATCO Pharma reports 35 per cent YoY increase in revenues

Pratik Shastri

NATCO Pharma Limited reported its results for the quarter ended September 30, 2018 during market hours on Monday. 
  
  
NATCO Pharma's consolidated revenue for the quarter came in at Rs. 583.5 crore as against Rs. 432.2 crore for the same period last year, registering 35  per cent yoy growth. EBITDA for the quarter rose by 104.5  per cent yoy to Rs. 260.5 crore with a corresponding margin expansion of 1517 bps. EBITDA margin for the quarter stood at 44.6  per cent. Net profit for the quarter came in at Rs. 181.6 crore, yoy increase of 115.2 per cent. The PAT margin for the quarter stood at 31 per cent. 
  
On Monday, the company's stock opened for trade at Rs. 780 per share on the BSE, and were up by 1.56 per cent after the results were declared and at 3:15 pm, it was trading at Rs. 785.55. While the benchmark index BSE Sensex was trading at 34,928 83 points, down from its last close. 

 

Previous Article Cipla reports 1 per cent YoY decline in revenue
Next Article Eveready Q2FY19 revenue down by 4.5 per cent YoY
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR